interleukin-7 to improve clinical outcomes in lymphopenic patients with covid-19 infection uk cohort
interleukin-7 to improve clinical outcomes in lymphopenic patients with covid-19 infection uk cohort
interleukin-7 restores lymphocytes in septic shock: the iris-7 randomized clinical trial.", "venet f, foray ap, villars-mechin a, malcus c, poitevin-later f, lepape a, monneret g. il-7 restores lymphocyte functions in septic patients.", "improvement of the absolute lymphocyte count (alc) of lymphopenic (alc1000/mm3) covid-19 infected participants out to approximately 30 days following initial study drug administration or hospital discharge (hd), whicheve [ time frame: 1 month ] a statistically significant increase of the absolute lymphocyte count (alc) from randomization to day 30 or hospital discharge secondary outcome measures : 1."


































)